I like the optimism in this, and the rightful identification of many important bottlenecks.
It's important to recognize that many of the remaining medical problems are very hard to solve. And while I'm still hopeful for relatively simple answers to some, successful interventions for others often require changes across multiple systems, and at economic or social costs we haven't been willing to bear. Identifying new technical solutions across all stages of research is important. But we also struggle to implement many basic interventions that already work.
These type of articles always start with low hanging fruit and then ignore or overlook that some problems are not at all like that. Different mechanisms altogether, like cancer or Alzheimer's. These are way harder.
A new large phase three trial found that one such drug, daraxonrasib, roughly doubled survival compared to standard chemotherapy
Yes, from 7 months to 14. This detail which the article omits and assumes the reader will not notice or factcheck. This is a recuring these of "works in progress" articles of making sweeping claims or omitting details.
I like the optimism in this, and the rightful identification of many important bottlenecks.
It's important to recognize that many of the remaining medical problems are very hard to solve. And while I'm still hopeful for relatively simple answers to some, successful interventions for others often require changes across multiple systems, and at economic or social costs we haven't been willing to bear. Identifying new technical solutions across all stages of research is important. But we also struggle to implement many basic interventions that already work.
These type of articles always start with low hanging fruit and then ignore or overlook that some problems are not at all like that. Different mechanisms altogether, like cancer or Alzheimer's. These are way harder.
A new large phase three trial found that one such drug, daraxonrasib, roughly doubled survival compared to standard chemotherapy
Yes, from 7 months to 14. This detail which the article omits and assumes the reader will not notice or factcheck. This is a recuring these of "works in progress" articles of making sweeping claims or omitting details.